- Home
- ZNTL vs ERH Comparison
ZNTL vs ERH Comparison
Compare ZNTL & ERH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- ERH
- Stock Information
- Founded
- ZNTL 2014
- ERH 2004
- Country
- ZNTL United States
- ERH United States
- Employees
- ZNTL N/A
- ERH N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- ERH Finance/Investors Services
- Sector
- ZNTL Health Care
- ERH Finance
- Exchange
- ZNTL Nasdaq
- ERH Nasdaq
- Market Cap
- ZNTL 105.8M
- ERH 108.0M
- IPO Year
- ZNTL 2020
- ERH N/A
- Fundamental
- Price
- ZNTL $1.67
- ERH $12.97
- Analyst Decision
- ZNTL Buy
- ERH
- Analyst Count
- ZNTL 6
- ERH 0
- Target Price
- ZNTL $6.53
- ERH N/A
- AVG Volume (30 Days)
- ZNTL 689.2K
- ERH 23.2K
- Earning Date
- ZNTL 11-11-2025
- ERH 01-01-0001
- Dividend Yield
- ZNTL N/A
- ERH 8.85%
- EPS Growth
- ZNTL N/A
- ERH N/A
- EPS
- ZNTL N/A
- ERH N/A
- Revenue
- ZNTL $26,865,000.00
- ERH N/A
- Revenue This Year
- ZNTL N/A
- ERH N/A
- Revenue Next Year
- ZNTL N/A
- ERH N/A
- P/E Ratio
- ZNTL N/A
- ERH N/A
- Revenue Growth
- ZNTL N/A
- ERH N/A
- 52 Week Low
- ZNTL $1.01
- ERH $7.97
- 52 Week High
- ZNTL $4.44
- ERH $10.91
- Technical
- Relative Strength Index (RSI)
- ZNTL 50.91
- ERH 85.03
- Support Level
- ZNTL $1.54
- ERH $12.01
- Resistance Level
- ZNTL $1.69
- ERH $12.99
- Average True Range (ATR)
- ZNTL 0.09
- ERH 0.13
- MACD
- ZNTL 0.00
- ERH 0.08
- Stochastic Oscillator
- ZNTL 54.35
- ERH 96.06
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.